Sanofi India
Sanofi India Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
0 of 3 strong
The short version
Insulin market growth expected to continue at a higher single-digit rate despite GLP-1 emergence, with analog insulin segment showing sustained double-digit growth. Insulin market is expected to sustain higher single-digit growth overall, with analog insulin segments showing double-digit growth.
From Sanofi India's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Insulin market growth expected to continue at a higher single-digit rate despite GLP-1 emergence, with analog insulin segment showing sustained double-digit growth.
- Sanofi's diabetes portfolio, including Lantus, Toujeo, and Soliqua, continues to grow robustly, powered by innovation and expanded access, especially in public sector markets.
- Expansion in public sector expected to accelerate growth, demonstrated by 70% growth in public sector sales from Toujeo and Soliqua.
- Efforts to leverage patient support programs, early diagnosis, and digital outreach in tier two and tier three markets aim to sustain demand.
- Export strategy focuses on offsetting losses in mature markets by growth in emerging markets and specialized site manufacturing.
2 more points from Sanofi India's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sanofi India said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sanofi India is focusing on operational excellence and has financial discipline on operating expenses without impacting projects that offer a return on investment.
- There is a strategy to increase manufacturing volume by bringing back certain products outsourced to Contract Manufacturing Organizations (CMOs) to the Goa site, which is being specialized for manufacturing certain worldwide products.
- The company is investing in innovation, including innovative devices like Bluetooth devices and AI platforms, aimed at simplifying patient experience, especially for insulin users.
- CSR investments continue with programs such as KiDS & Diabetes in Schools and Mobile Medical Units, expanding into new regions like Madhya Pradesh.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanofi India said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Sanofi India's call on order book
Create a free account to keep reading this call
Sanofi India — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹438 Cr, net profit ₹84 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanofi India Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanofi India and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanofi India Q1 FY27 results?
Insulin market growth expected to continue at a higher single-digit rate despite GLP-1 emergence, with analog insulin segment showing sustained double-digit growth. Insulin market is expected to sustain higher single-digit growth overall, with analog insulin segments showing double-digit growth.
What is Sanofi India share price analysis?
Sanofi India currently shows a below-average growth signal. The stock trades at a P/E of 22.5 with a market cap of ₹7,722 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanofi India planning capital expenditure?
Sanofi India is focusing on operational excellence and has financial discipline on operating expenses without impacting projects that offer a return on investment.
Keep Sanofi India on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.